Fresenius Kabi

We are excited to be part of the 32nd United European Gastroenterology Week (UEG) in Vienna, Austria, from October 12-15, 2024! Join us to discover the future of gastroenterology. 🩺 📅 We are also hosting a symposium and would love to see you there: "Difficult-To-Treat Crohn’s Disease. From Monotherapy to Dual Targeted Therapy: Towards a New Paradigm?" on October 14 at 5:30 p.m. CEST, chaired by Prof. Laurent Peyrin-Biroulet (France) and featuring expert insights from Prof. Edouard Louis (Belgium) and Prof. Vipul Jairath (Canada). We look forward to connecting with you in Vienna and exploring our biosimilars portfolio! #UEGweek #Gastroenterology #Biopharma #CommmittedToLife UEG - United European Gastroenterology

Supporting breast cancer patients is essential in the fight against a disease that affects millions of lives worldwide. Every patient deserves access to affordable, high-quality treatments that offer hope and a path to recovery. Through a range of oncology therapies, we are committed to making life-saving treatments more accessible and affordable. These options are critical for healthcare professionals as they work tirelessly to provide the best possible care for patients battling breast cancer. Across the Fresenius family, this mission is shared by our colleagues from Helios and Quirónsalud, two of Europe’s leading healthcare providers. Both are deeply dedicated to raising awareness, improving early detection, and offering personalized, cutting-edge treatments. Together, we are helping to ensure that patients and their caregivers have the resources and support they need during every stage of their journey. Join us throughout October as we raise awareness and support those impacted by breast cancer. Discover the thoughtful and remarkable activities our colleagues around the world are engaging in to highlight this important cause. Together, we can make a difference for patients, healthcare professionals, and families everywhere. 🎗️💪 #BreastCancerAwareness #CommittedToLife

mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals entered a second global licensing agreement for the development of an oncology biosimilar candidate. Great news and clear indicator of our shared commitment to making high-quality, affordable treatments accessible to patients worldwide in line with #FutureFresenius. Read more here: https://lnkd.in/eDJNezag #Biopharma #CommittedToLife

We welcome Molly Benson in her new role as Senior Vice President of Region US Biopharma at Fresenius Kabi. With Molly’s appointment, we are continuing our path of transformation to further develop the innovative strength of our Biopharma business in the US. #Vision2026 #FutureFresenius #TeamFresenius #CommittedToLife

📚 School start: A lesson in empathy and understanding 📚 As children with special medical needs start school, they often face challenges that many of us might never experience. They enter an unfamiliar environment where their classmates may not be aware of the complexities they navigate daily. This year, we were inspired by the courage of Leo, the son of one of our colleagues, who has been receiving home parenteral nutrition since his early days. Accompanied by his cuddly toy, Leo turned his new experience into an educational opportunity. He explained to his classmates why he uses a wheeled suitcase instead of a backpack and the importance of being careful around his catheter. Since the catheter is placed between his chest and his shoulder, wearing a traditional backpack would be too risky. Without the suitcase, he would have to carry a backpack with his hands all day long. With the help of his toy monkey and a demo catheter, Leo shared his story and explained how his parenteral nutrition works, making it easier for his peers to understand and support him. Stories like these highlight the incredible resilience of children and remind us of the supportive role we can all play in embracing and understanding differences. We would love to hear how you or someone you know explains their parenteral nutrition needs. Comment below to share your story and inspire others! #MedicalNutrition #ParenteralNutrition #CommittedToLife

BREAKING: The FDA has approved our fourth biosimilar. Our Ustekinumab biosimilar, in partnership with Formycon AG, is indicated for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis in adult patients, moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy, and active psoriatic arthritis in patients 6 years and older. It is contraindicated in patients with significant hypersensitivity to Ustekinumab products or to any of its excipients.    “This milestone approval of our fourth biosimilar will enhance the accessibility of high-quality, affordable biologic treatments for both patients and healthcare providers in the U.S.,” said Arunesh Verma, President, Fresenius Kabi USA. “We’re pleased to continue our efforts to support broader access to essential biologics and contribute to a more sustainable healthcare system.”    Read the news release: https://lnkd.in/e3fhQJMD     Please see Important Safety Information for Ustekinumab-aauz at  https://lnkd.in/eNWd7Nj3.   #FDAappoved #Biosimilars #FutureFresenius #CommittedToLife

On today’s World Heart Day, we honor the tireless efforts of healthcare professionals who stand on the frontlines of cardiac care, making life-saving decisions every day. With heart disease continuing to be the leading cause of death globally, access to effective, high-quality treatments is more critical than ever. At Fresenius Kabi, we are committed to supporting healthcare professionals in providing the best possible care for patients. From managing arrhythmias to improving cardiac output, our portfolio of affordable generics helps to ensure that essential treatments are always within reach – empowering healthcare systems to deliver better outcomes, even in the most challenging situations. Together, we can continue to make a difference, one heartbeat at a time. ❤️ #CardiacCare #Pharma #CommittedToLife

Another important milestone for our #Biosimilars portfolio with our ustekinumab biosimilar, the fourth biosimilar product from Fresenius Kabi, receiving European Commission (EC) approval. Together with our license partner Formycon, we are proud to continue to deliver high-quality and affordable therapies for autoimmune diseases. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma business, which is a substantial cornerstone of #Vision2026 and #FutureFresenius. Learn more: https://lnkd.in/eEcjckBt #Biopharma #CommittedToLife

How can families better support loved ones with dementia? Paola Gava has an answer. She developed MED-DEM, an online platform that helps relatives of people with dementia by providing easy access to essential information and practical guidance. Additionally, it enables fast communication between family caregivers, nurses, and the medical team. 💻🤝 The nursing student from Germany was recognized for her work with the Queen Silvia Nursing Award 2023. 🏆 During a festive ceremony at the Royal Palace in Stockholm, Her Majesty Queen Silvia of Sweden personally presented the award to the international prize winners, including Paola Gava. The award acknowledges that Paola's approach not only helps overcome practical challenges but also promotes the emotional well-being of family members. At Fresenius Kabi, we believe that excellent nursing deserves recognition. Fresenius Kabi Germany has proudly supported the Queen Silvia Nursing Award since it was established in 2013. 👉 If you are a nurse or nursing student from Sweden, Finland, Germany, Lithuania, or Poland with an innovative idea for the future of care, especially for patients with dementia, submit it now! Apply for the Queen Silvia Nursing Award 2024 by November 1, 2024: https://lnkd.in/dVK-q6j #QSNA2023 #QueenSilviaNursingAward #Nursing #CommittedToLife Queen Silvia Nursing Award International Photo: © Yanan Li & Swedish Care International

We are happy to invite you to join us at the ESICM 2024 in Barcelona! As your partner in intensive care, we will be showcasing our integrated solutions in MedTech, pharmaceuticals, and medical nutrition. 🌍 🔍 Attend our symposium on "Navigating Nutritional Pathways: Insights from a Patient’s Journey" and connect with industry leaders Prof. Mette Berger, Prof. Christian Stoppe and Dr. Karolien Dams for valuable insights into intensive care nutrition. 📚 Stay tuned for our live sessions and join the conversation about the future of intensive care. #ESICM24 #IntensiveCare #MedicalNutrition #MedicalDevices #CommittedToLife European Society of Intensive Care Medicine - ESICM